Loading
Liver Disease Diagnosis and Treatment · Journal article
Expert Review of Pharmacoeconomics & Outcomes Research · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a health economic model estimating the annual price of resmetirom at which its cost-effectiveness ratio would meet each country's willingness-to-pay threshold. The model projects QALY gains ranging from 0.47 to 1.28 per patient depending on country and suggests substantial price reductions would be needed for cost-effectiveness in public health systems.
Health economic model; annual-cycle Markov model. Adults with noncirrhotic MASH and moderate-to-advanced fibrosis (F2-F3) in four countries: China, the United Kingdom, France, and Germany. Intervention: Resmetirom plus standard of care. Compared with: Standard of care alone. Four countries: China, the United Kingdom, France, and Germany.
Resmetirom increased QALYs by 0.47 (China), 0.96 (UK), 1.28 (France), and 1.07 (Germany) Estimated value-based annual prices were US$3,573 (China), US$6,487 (UK), US$9,334 (France), and US$10,656 (Germany) At current US annual price, ICERs exceeded country-specific willingness-to-pay thresholds in all four settings
Actual efficacy and safety data from the resmetirom trial are not provided; QALY estimates are derived from the model, not reported from clinical trials
This analysis informs payers and manufacturers on pricing strategy but does not directly guide clinical treatment decisions. Clinicians should note that cost-effectiveness depends heavily on negotiated price and country-specific health-system budgets, not on the efficacy findings themselves.
This is a modelling study that estimates hypothetical value-based prices; it does not report clinical trial data, real-world outcomes, or actual pricing decisions, and raises questions about pricing strategy rather than answering clinical or health-economic questions grounded in observed data.
As stated by the source record.
Quoted from the source exactly as published.
This analysis informs payers and manufacturers on pricing strategy but does not directly guide clinical treatment decisions. Clinicians should note that cost-effectiveness depends heavily on negotiated price and country-specific health-system budgets, not on the efficacy findings themselves.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Resmetirom is the first approved pharmacological treatment for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis (F2-F3). We estimated its value-based annual price in China, the United Kingdom, France, and Germany from the health-care payer perspective. RESEARCH DESIGN AND METHODS: We developed an annual-cycle Markov model for eligible F2-F3 patients receiving standard of care (SoC) or resmetirom plus SoC. Country-specific epidemiology, costs, and willingness-to-pay (WTP) thresholds were applied. Value-based pricing (VBP) was the annual price at which the incremental cost-effectiveness ratio (ICER) equaled the country-specific WTP threshold per quality-adjusted life-year (QALY). Analyses included ICERs at the current US price and probabilistic sensitivity analysis. RESULTS: Resmetirom increased life-years (LYs) by 0.30, 0.71, 0.96, and 0.80 in China, the UK, France, and Germany, with QALY gains of 0.47, 0.96, 1.28, and 1.07. Estimated VBPs were US$3,573, US$6,487, US$9,334, and US$10,656, respectively. At the current US annual price, ICERs exceeded country-specific WTP thresholds in all settings. CONCLUSIONS: Price reductions toward country-specific VBPs would be required for resmetirom to be cost-effective in these publicly financed health systems.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.